MaaT Pharma (EURONEXT: MAAT) announced the publication of CHRONOS, a large, multicenter, retrospective cohort study evaluating real-world outcomes of third-line (3L) systemic therapies, excluding microbiotherapy, in 59 patients with steroid- and ruxolitinib-refractory acute graft-versus-host-disease (aGvHD) with gastrointestinal involvement, in the peer-reviewed journal Bone Marrow Transplantation, the official journal of the European Society for Blood and Marrow Transplantation (EBMT).
The article is titled “Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure.” The CHRONOS data have also been presented during a poster session by Johannes Clausen, MD, hematologist at Ordensklinikum Linz Elisabethinen, Hematology Department, Linz, Austria and primary author of the publication at the 2026 EBMT Annual Congress.
In a statement, Dr. Clausen commented, “CHRONOS provides a contemporary reference point for third-line GI-aGvHD, underscoring both the gravity of this condition and the persistent lack of standardized, effective therapies. The study highlights the stark limitations of current options and sets a meaningful new benchmark for this challenging clinical setting.”
